Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.16 USD | -9.41% | -8.61% | +9.03% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Evolution of the average Target Price on C4 Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering C4 Therapeutics, Inc.
Stifel Nicolaus | |
Morgan Stanley | |
JPMorgan Chase | |
BMO Capital | |
HC Wainwright | |
UBS | |
Evercore ISI | |
BofA Securities | |
Wells Fargo Securities | |
Credit Suisse | |
SVB Leerink | |
Brookline Capital Management |
EPS Revisions
- Stock Market
- Equities
- CCCC Stock
- Consensus C4 Therapeutics, Inc.